Evidence map›Paper›PMID 41182611›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Cloning-Free Genome Editing by CRISPR/T7RNAP/Cas9 in Trypanosoma cruzi.

Miguel A Chiurillo, Milad Ahmed, César González, Juliana Nunes Rosón, Asima Das, Noelia Lander

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miguel A ChiurilloDepartment of Biological Sciences, University of Cincinnati, Cincinnati, OH, USA. chiurima@ucmail.uc.edu.
Milad AhmedDepartment of Biological Sciences, University of Cincinnati, Cincinnati, OH, USA.
César GonzálezDepartment of Biological Sciences, University of Cincinnati, Cincinnati, OH, USA.
Juliana Nunes RosónDepartment of Biological Sciences, University of Cincinnati, Cincinnati, OH, USA.
Asima DasDepartment of Biological Sciences, University of Cincinnati, Cincinnati, OH, USA.
Noelia LanderDepartment of Biological Sciences, University of Cincinnati, Cincinnati, OH, USA. landernm@ucmail.uc.edu.

Funding

Large-scale CRISPR screening of essential calcium-related genes in the human parasite Tr. cruziR00AI137322 · NIAID · UNIVERSITY OF CINCINNATI · PI LANDER, NOELIA · 2021 to 2022
$498k
Barcode screening of essential protein kinases in the life cycle progression of Trypanosoma cruziR21AI178573 · NIAID · UNIVERSITY OF CINCINNATI · PI CHIURILLO, MIGUEL A · 2023 to 2024
$446k
Characterization of cAMP signaling microdomains in the human pathogen Trypanosoma cruziR21AI182544 · NIAID · UNIVERSITY OF CINCINNATI · PI LANDER, NOELIA · 2025 to 2025
$445k
American Heart Association-American Stroke Association 23IPA1054779NIAID NIH HHS R00 AI137322NIAID NIH HHS R21 AI178573NIAID NIH HHS R21 AI182544
6 · The paper itself

Abstract

The genetic manipulation of the human parasite Trypanosoma cruzi has been significantly improved since the implementation of the CRISPR/Cas9 technology for genome editing in this organism. Initially, the system was successfully used for gene knockout and endogenous C-terminal tagging in T. cruzi. Recently, an updated version of this technology has been used for gene complementation, site-directed mutagenesis, and N-terminal tagging in trypanosomatids. This cloning-free strategy, called CRISPR/T7RNAP/Cas9, is extremely useful for identifying essential genes when null mutants are not viable. Mutant cell lines obtained by this new system have been used for the functional characterization of proteins in different developmental stages of this parasite's life cycle, including infective trypomastigotes and intracellular amastigotes. In this chapter, we describe the methodology to achieve genome editing by CRISPR/T7RNAP/Cas9 in T. cruzi. Our method involves the generation of T. cruzi epimastigotes that constitutively express the T7 RNA polymerase (T7RNAP) and SpCas9, and their co-transfection with an sgRNA template and donor DNA(s) as polymerase chain reaction (PCR) products. Using this strategy, we have generated genetically modified parasites in 2-3 weeks without the need for gene cloning, cell sorting, or having to perform several transfection attempts to verify the sgRNA efficiency for targeting the gene of interest. The methodology has been organized according to three main genetic purposes: gene knockout, gene complementation of knockout cell lines, and endogenous (N- or C-terminal) tagging in T. cruzi.

Indexed as

CRISPR-Cas SystemsDNA-Directed RNA PolymerasesGene EditingGenome, ProtozoanTrypanosoma cruziViral ProteinsCloning, MolecularGene Knockout TechniquesHumansbacteriophage T7 RNA polymeraseDNA-Directed RNA PolymerasesViral ProteinsCRISPR/Cas9Endogenous gene taggingGene complementationGene knockoutGenome editingT7 RNA polymeraseTrypanosoma cruzi

Identifiers

PMID41182611
PMCPMC12974534

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.